Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: BNC210 for Social Anxiety Disorder
NCT05193409Phase 2Completed
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soclenicant in Social Anxiety Disorder (SAD), sponsored by Neuphoria Therapeutics Inc.. Started Feb 2022; status: completed.
02
Drugs
soclenicant
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT05193409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193409.